Fumaryl acetone | 62966-21-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Fumaryl acetone
• 英文别名: cyclohept-6-ene-1,3,5-trione
• CAS: 62966-21-6
• 化学式: C₇H₆O₃
• 分子量: 138.12
• InChiKey: LRBCDZWXQXOVTN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  51.2
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES
  申请人：——

  公开号：US20030109555A1

  公开（公告）日：2003-06-12

  The present invention relates to Glutathione S-transferase (GST)/Reduced Glutathione (GSH) as a means for the in-vivo release of a drug that has been conjugated to specific electrophilic moieties via a sulfonamide bond. The drug may be an anticancer agent (or one with other therapeutic properties) carrying a free —NH— which has been derivatized by the attachment of an electrophile containing a moiety, such as p-CN— or p-NO 2-pyridinylsulfonyl groups, or p-NO 2- or 2,4 dinitrophenylsulfonyl groups, or suitable derivatives thereof, to make a prodrug. Optionally, the sulfonamide moiety may have attached to it a targeting molecule. The present invention also provides Glutathione S-transferase (GST)/Reduced Gluthathione (GSH) as a means for the release of a protected amino derivative that has been conjugated to specific electrophilic moieties via a sulfonamide bond. The precursor is a synthetic intermediate carrying a free —NH— which has been derivatized by the attachment of an electrophile via a sulfonamide bond.

  本发明涉及谷胱甘肽S-转移酶（GST）/还原谷胱甘肽（GSH）作为体内释放已通过磺酰胺键与特定亲电性基团结合的药物的手段。该药物可能是一种抗癌剂（或具有其他治疗性能）携带有一个自由的-NH-，通过连接含有一个基团的亲电子试剂，如p-CN-或p-NO2-吡啶基磺酰基团，或p-NO2-或2,4-二硝基苯基磺酰基团，或其适当的衍生物，制备成前药。可选地，磺酰胺基团上可能连接有一个靶向分子。本发明还提供谷胱甘肽S-转移酶（GST）/还原谷胱甘肽（GSH）作为释放已通过磺酰胺键与特定亲电性基团结合的保护氨基衍生物的手段。前体是一种合成中间体，携带有一个自由的-NH-，通过连接一个亲电子试剂通过磺酰胺键进行衍生化。
• MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF AROMATICS, 2,4-PENTADIENOATE AND 1,3-BUTADIENE
  申请人：Osterhout Robin E.

  公开号：US20120021478A1

  公开（公告）日：2012-01-26

  The invention provides non-naturally occurring microbial organisms having a toluene, benzene, p-toluate, terephthalate, (2-hydroxy-3-methyl-4-oxobutoxy)phosphonate, (2-hydroxy-4-oxobutoxy)phosphonate, benzoate, styrene, 2,4-pentadienoate, 3-butene-1ol or 1,3-butadiene pathway. The invention additionally provides methods of using such organisms to produce toluene, benzene, p-toluate, terephthalate, (2-hydroxy-3-methyl-4-oxobutoxy)phosphonate, (2-hydroxy-4-oxobutoxy)phosphonate, benzoate, styrene, 2,4-pentadienoate, 3-butene-1ol or 1,3-butadiene.

  本发明提供了一种非自然出现的微生物有甲苯、苯、对甲苯酸、对苯二甲酸、(2-羟基-3-甲基-4-氧代丁氧基)膦酸酯、(2-羟基-4-氧代丁氧基)膦酸酯、苯甲酸、苯乙烯、2,4-戊二烯酸、3-丁烯-1-醇或1,3-丁二烯代谢途径。此外，本发明还提供了使用这些微生物制备甲苯、苯、对甲苯酸、对苯二甲酸、(2-羟基-3-甲基-4-氧代丁氧基)膦酸酯、(2-羟基-4-氧代丁氧基)膦酸酯、苯甲酸、苯乙烯、2,4-戊二烯酸、3-丁烯-1-醇或1,3-丁二烯的方法。
• MICROORGANISMS FOR PRODUCING METHACRYLIC ACID AND METHACRYLATE ESTERS AND METHODS RELATED THERETO
  申请人：BURK Mark J.

  公开号：US20130065279A1

  公开（公告）日：2013-03-14

  The invention provides a non-naturally occurring microbial organism having a methacrylic acid, methacrylate ester, 3-hydroxyisobutyrate and/or 2-hydroxyisobutyrate pathway. The microbial organism contains at least one exogenous nucleic acid encoding an enzyme in a methacrylic acid pathway. The invention additionally provides a method for producing methacrylic acid, methacrylate ester, 3-hydroxyisobutyrate and/or 2-hydroxyisobutyrate. The method can include culturing methacrylic acid, methacrylate ester, 3-hydroxyisobutyrate and/or 2-hydroxyisobutyrate producing microbial organism, where the microbial organism expresses at least one exogenous nucleic acid encoding a methacrylic acid pathway enzyme in a sufficient amount to produce methacrylic acid, methacrylate ester, 3-hydroxyisobutyrate and/or 2-hydroxyisobutyrate, under conditions and for a sufficient period of time to produce methacrylic acid, methacrylate ester, 3-hydroxyisobutyrate and/or 2-hydroxyisobutyrate.

  本发明提供了一种非自然存在的微生物，其具有甲基丙烯酸、甲基丙烯酸酯、3-羟基异丁酸和/或2-羟基异丁酸途径。该微生物含有至少一个外源性核酸，编码甲基丙烯酸途径中的一种酶。本发明还提供了一种生产甲基丙烯酸、甲基丙烯酸酯、3-羟基异丁酸和/或2-羟基异丁酸的方法。该方法可以包括培养产生甲基丙烯酸、甲基丙烯酸酯、3-羟基异丁酸和/或2-羟基异丁酸的微生物，在条件和足够的时间下，微生物表达至少一个外源性核酸编码的甲基丙烯酸途径酶，以产生甲基丙烯酸、甲基丙烯酸酯、3-羟基异丁酸和/或2-羟基异丁酸。
• Method of treating cancer by oral administration of acetate composition comprising magnesium acetate, calcium acetate or ethylacetate
  申请人：Ott David Michael

  公开号：US10583106B2

  公开（公告）日：2020-03-10

  Genetic and epigenetic diseases and disorders are treated with FDA approved dietary compositions in the form of dietary supplements and nutraceuticals. The diseases and disorders to be treated include Rett syndrome, trinucleotide repeat diseases such as Fragile X syndrome, memory impairment, chronic inflammation, pre-cancerous conditions which involve cancer stem cells, and post-cancerous conditions which involve cancer stem cells which have survived in spite of cancer treatment. Treatment options include prophylactic treatment which is initiated prior to the development of the symptoms of the disease or disorder.

  遗传和表观遗传疾病和失调可通过食品及药物管理局批准的膳食补充剂和营养保健品形式的膳食组合物进行治疗。要治疗的疾病和失调包括雷特综合征、三核苷酸重复疾病（如脆性 X 综合征）、记忆障碍、慢性炎症、涉及癌症干细胞的癌前病症，以及涉及癌症干细胞的癌后病症，这些癌症干细胞在癌症治疗后仍然存活。治疗方案包括预防性治疗，即在出现疾病或失调症状之前开始治疗。
• Method of dietary treatment for genetic and epigenetic diseases and disorders
  申请人：Ott David Michael

  公开号：US11026911B2

  公开（公告）日：2021-06-08

  Genetic and epigenetic diseases and disorders are treated with FDA approved dietary compositions in the form of dietary supplements and nutraceuticals. The diseases and disorders to be treated include Rett syndrome, trinucleotide repeat diseases such as Fragile X syndrome, memory impairment, chronic inflammation, pre-cancerous conditions which involve cancer stem cells, and post-cancerous conditions which involve cancer stem cells which have survived in spite of cancer treatment. Treatment options include prophylactic treatment which is initiated prior to the development of the symptoms of the disease or disorder.

  遗传和表观遗传疾病和失调可通过食品及药物管理局批准的膳食补充剂和营养保健品形式的膳食组合物进行治疗。要治疗的疾病和失调包括雷特综合征、三核苷酸重复疾病（如脆性 X 综合征）、记忆障碍、慢性炎症、涉及癌症干细胞的癌前病症，以及涉及癌症干细胞的癌后病症，这些癌症干细胞在癌症治疗后仍然存活。治疗方案包括预防性治疗，即在出现疾病或失调症状之前开始治疗。